Increasing uptake of live attenuated influenza vaccine among children in the United States, 2008–2014

• Published in: Vaccine Vol. 33; no. 1; pp. 22 - 24
• Main Authors: Rodgers, Loren, Pabst, Laura J, Chaves, Sandra S
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01-01-2015; Elsevier Limited
• Subjects: Age; Allergy and Immunology; Child; Child, Preschool; Disease control; Female; Health services; Hospitals; Humans; Immunization; Immunization information systems; Influenza; Influenza vaccines; Influenza Vaccines - administration & dosage; Influenza, Human; Influenza, Human - prevention & control; Information systems; Male; Population; Registries; Studies; Trends; United States; Vaccination; Vaccination - methods; Vaccination - trends; Vaccination - utilization; Vaccine coverage; Vaccines; Vaccines, Attenuated - administration & dosage; United States; Oregon; Minnesota; United States > US; North Dakota; Wisconsin; Michigan; USA, Minnesota; USA, North Dakota; Influenza vaccines; Immunization information systems; Vaccine coverage; Vaccination; Influenza, Human; Child, Preschool; Registries
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2014.11.006

Abstract The Advisory Committee on Immunization Practices (ACIP) recommends annual influenza vaccination for all persons in the United States aged ≥6 months. On June 25, 2014, ACIP preferentially recommended live attenuated influenza vaccine (LAIV) for healthy children aged 2–8 years [1] . Little is known about national LAIV uptake. To determine uptake of LAIV relative to inactivated influenza vaccine, we analyzed vaccination records from six immunization information system sentinel sites (approximately 10% of US population). LAIV usage increased over time in all sites. Among children 2–8 years of age vaccinated for influenza, exclusive LAIV usage in the collective sentinel site area increased from 20.1% (2008–09 season) to 38.0% (2013–14). During 2013–14, at least half of vaccinated children received LAIV in Minnesota (50.0%) and North Dakota (55.5%). Increasing LAIV usage suggests formulation acceptability, and this preexisting trend offers a favorable context for implementation of ACIP's preferential recommendation.